A life-extending prostate cancer drug will continue to only be available to sufferers who have already undergone chemotherapy, the NHS financial watchdog said.
In final draft guidance reassessing the use in the NHS in England of abiraterone, the National Institute for Health and Care Excellence (Nice) ruled that to extend the availability of the drug was "not cost effective at its current price."
There is "clear evidence" that the use of abiraterone before chemotherapy gives patients "longer healthier lives," according to The Institute of Cancer Research, where the drug was discovered.
Nice's chief executive Sir Andrew Dillion said: "We know how important it is for patient to have the option to delay chemotherapy and its associated side affects, so we are disappointed not to be able to recommend abiraterone for use in this way.
"However, the manufacturer's own economic model demonstrated that the drug does not offer enough benefit to justify its price."
More top news
Marjorie and Micheal Cawdery, both 83, were found dead in their house in Portadown, Northern Ireland on Friday.
Ann Myatt, who is contesting Jo Cox's former seat, told a hustings: "We've not yet shot anybody so that's wonderful."
The 26-year-old said she was moving on to the "next big chapter" - which includes a new show about her venture into motherhood.